Humacyte (NASDAQ:HUMA) Shares Gap Up to $4.80

Humacyte, Inc. (NASDAQ:HUMA) shares gapped up prior to trading on Monday . The stock had previously closed at $4.80, but opened at $5.36. Humacyte shares last traded at $6.10, with a volume of 2,177,809 shares trading hands.

Analyst Ratings Changes

A number of research firms have weighed in on HUMA. Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price on shares of Humacyte in a research note on Tuesday, March 26th. Benchmark reissued a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Humacyte in a research report on Tuesday.

Humacyte Trading Down 4.8 %

The firm’s 50-day moving average price is $5.95 and its 200-day moving average price is $4.22. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.61. The company has a market cap of $608.50 million, a P/E ratio of -5.11 and a beta of 1.52.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, May 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). As a group, equities research analysts expect that Humacyte, Inc. will post -0.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 271,518 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the sale, the director now owns 4,559,140 shares of the company’s stock, valued at approximately $33,281,722. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Gordon M. Binder purchased 50,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average price of $6.78 per share, with a total value of $339,000.00. Following the purchase, the director now directly owns 160,000 shares in the company, valued at $1,084,800. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Brady W. Dougan sold 271,518 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the completion of the transaction, the director now directly owns 4,559,140 shares of the company’s stock, valued at approximately $33,281,722. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 54,412 shares of company stock valued at $369,107 and have sold 1,628,820 shares valued at $12,464,121. 23.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently bought and sold shares of HUMA. Vanguard Group Inc. grew its stake in Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after buying an additional 896,415 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in shares of Humacyte in the 1st quarter valued at $972,000. Private Advisor Group LLC boosted its stake in shares of Humacyte by 232.7% in the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after purchasing an additional 222,144 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of Humacyte by 139.5% in the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company’s stock valued at $1,043,000 after purchasing an additional 207,333 shares in the last quarter. Finally, Rokos Capital Management LLP boosted its stake in shares of Humacyte by 122.5% in the 3rd quarter. Rokos Capital Management LLP now owns 200,000 shares of the company’s stock valued at $587,000 after purchasing an additional 110,097 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.